NCT02187250View on ClinicalTrials.gov

PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
PCOSObesity
Interventions
DRUG

metformin

DRUG

liraglutide

DRUG

roflumilast

Trial Locations (1)

1000

University Medical Center Ljubljana, Ljubljana

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER

NCT02187250 - PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter